Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Int J Hyperthermia ; 36(1): 277-294, 2019.
Article in English | MEDLINE | ID: mdl-30676101

ABSTRACT

Quality assurance (QA) guidelines are essential to provide uniform execution of clinical hyperthermia treatments and trials. This document outlines the clinical and technical consequences of the specific properties of interstitial heat delivery and specifies recommendations for hyperthermia administration with interstitial techniques. Interstitial hyperthermia aims at tumor temperatures in the 40-44 °C range as an adjunct to radiation or chemotherapy. The clinical part of this document imparts specific clinical experience of interstitial heat delivery to various tumor sites as well as recommended interstitial hyperthermia workflow and procedures. The second part describes technical requirements for quality assurance of current interstitial heating equipment including electromagnetic (radiative and capacitive) and ultrasound heating techniques. Detailed instructions are provided on characterization and documentation of the performance of interstitial hyperthermia applicators to achieve reproducible hyperthermia treatments of uniform high quality. Output power and consequent temperature rise are the key parameters for characterization of applicator performance in these QA guidelines. These characteristics determine the specific maximum tumor size and depth that can be heated adequately. The guidelines were developed by the ESHO Technical Committee with participation of senior STM members and members of the Atzelsberg Circle.


Subject(s)
Hyperthermia, Induced/methods , Quality Assurance, Health Care/methods , Guidelines as Topic , Humans , Temperature
2.
Radiat Res ; 185(5): 516-26, 2016 05.
Article in English | MEDLINE | ID: mdl-27135969

ABSTRACT

Cerium oxide nanoparticles (CNPs) have a unique surface regenerative property and can efficiently control reactive oxygen/nitrogen species. To determine whether treatment with CNPs can mitigate the delayed effects of lung injury after acute radiation exposure, CBA/J mice were exposed to 15 Gy whole-thorax radiation. The animals were either treated with nanoparticles, CNP-18 and CNP-ME, delivered by intraperitoneal injection twice weekly for 4 weeks starting 2 h postirradiation or received radiation treatment alone. At the study's end point of 160 days, 90% of the irradiated mice treated with high-dose (10 µM) CNP-18 survived, compared to 10% of mice in the radiation-alone (P < 0.0001) and 30% in the low-dose (100 nM) CNP-18. Both low- and high-dose CNP-ME-treated irradiated mice showed increased survival rates of 40% compared to 10% in the radiation-alone group. Multiple lung functional parameters recorded by flow-ventilated whole-body plethysmography demonstrated that high-dose CNP-18 treatment had a significant radioprotective effect on lethal dose radiation-induced lung injury. Lung histology revealed a significant decrease (P < 0.0001) in structural damage and collagen deposition in mice treated with high-dose CNP-18 compared to the irradiated-alone mice. In addition, significant reductions in inflammatory response (P < 0.01) and vascular damage (P < 0.01) were observed in the high-dose CNP-18-treated group compared to irradiated-alone mice. Together, the findings from this preclinical efficacy study clearly demonstrate that CNPs have both clinically and histologically significant mitigating and protective effects on lethal dose radiation-induced lung injury.


Subject(s)
Cerium/chemistry , Cerium/pharmacology , Lung Injury/prevention & control , Nanoparticles/chemistry , Radiation Injuries, Experimental/prevention & control , Animals , Body Weight/drug effects , Body Weight/radiation effects , Female , Lung/drug effects , Lung/pathology , Lung/radiation effects , Lung Injury/pathology , Lung Injury/physiopathology , Mice , Organ Size/drug effects , Organ Size/radiation effects , Radiation Injuries, Experimental/pathology , Radiation Injuries, Experimental/physiopathology , Respiration/drug effects , Respiration/radiation effects , Survival Analysis
3.
Br J Cancer ; 106(5): 916-22, 2012 Feb 28.
Article in English | MEDLINE | ID: mdl-22333602

ABSTRACT

BACKGROUND: In early-stage breast cancer, adjuvant chemotherapy is associated with significant systemic toxicity with only a modest survival benefit. Therefore, there is considerable interest in identifying predictive markers of response to therapy. Doxorubicin, one of the most common drugs used to treat breast cancer, is an anthracycline chemotherapeutic agent, a class of drugs known to be affected by hypoxia. Accordingly, we examined whether expression of the endogenous hypoxia marker carbonic anhydrase IX (CA IX) is predictive of outcome in early-stage breast cancer patients treated with doxorubicin. METHODS: We obtained 209 early-stage pre-treatment surgically-resected breast tumours from patients, who received doxorubicin in their chemotherapeutic regimen and had >10 years of follow-up. Immunohistochemistry was used to detect CA IX, and we used fluorescence in situ hybridisation to detect both human epidermal growth factor receptor (HER2) and DNA topoisomerase II-alpha (TOP2A) gene amplification. RESULTS: Carbonic anhydrase IX intensity was significantly correlated with progression-free survival (PFS) and overall survival (OS) in patients receiving 300 mg m(-2) of doxorubicin (HR=1.82 and 3.77; P=0.0014 and 0.010, respectively). There was a significant, inverse correlation between CA IX score and oestrogen receptor expression, but no significant correlations were seen with either HER2 or TOP2A ratio. CONCLUSION: We demonstrate that CA IX expression is correlated with worse PFS and OS for breast cancer patients treated with doxorubicin, independent of HER2 or TOP2A gene amplification. This study provides evidence that using CA IX to detect hypoxia in surgically-resected breast tumours may be of clinical use in choosing an appropriate chemotherapy regimen.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Antigens, Neoplasm/metabolism , Breast Neoplasms/drug therapy , Carbonic Anhydrases/metabolism , Doxorubicin/therapeutic use , Drug Resistance, Neoplasm , Adult , Aged , Antigens, Neoplasm/genetics , Biomarkers, Tumor , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Carbonic Anhydrase IX , Cell Hypoxia , Chemotherapy, Adjuvant , DNA Topoisomerases, Type II/genetics , DNA-Binding Proteins/genetics , Disease-Free Survival , Female , Gene Amplification , Genes, erbB-2 , Humans , Middle Aged , Poly-ADP-Ribose Binding Proteins
4.
Radiat Res ; 173(2): 165-74, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20095848

ABSTRACT

To investigate the relationship of HIF1alpha signaling to oxidative stress, tissue hypoxia, angiogenesis and inflammation, female Fischer 344 rats were irradiated to the right hemithorax with a fractionated dose of 40 Gy (8 Gy x 5 days). The lung tissues were harvested before and at 4, 6, 10, 14, 18, 22 and 26 weeks after irradiation for serial studies of biological markers, including markers for hypoxia (HIF1alpha, pimonidazole and CA IX), oxidative stress (8-OHdG), and angiogenesis/capillary proliferation (VEGF/CD 105), as well as macrophage activation (ED-1) and cell signaling/fibrosis (NFkappaB, TGFbeta1), using immunohistochemistry and Western blot analysis. HIF1alpha staining could be observed as early as 4 weeks postirradiation and was significantly increased with time after irradiation. Importantly, HIF1alpha levels paralleled oxidative stress (8-OHdG), tissue hypoxia (pimonidazole and CA IX), and macrophage accumulation consistent with inflammatory response. Moreover, changes in HIF1alpha expression identified by immunohistochemistry assay parallel the changes in TGFbeta1, VEGF, NFkappaB and CD 105 levels in irradiated lungs. These results support the notion that oxidative stress and tissue hypoxia might serve as triggering signals for HIF1alpha activity in irradiated lungs, relating to radiation-induced inflammation, angiogenesis and fibrosis.


Subject(s)
Dose Fractionation, Radiation , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Hypoxia/metabolism , Lung/radiation effects , Oxidative Stress , Signal Transduction , 8-Hydroxy-2'-Deoxyguanosine , Animals , Blotting, Western , Deoxyguanosine/analogs & derivatives , Deoxyguanosine/metabolism , Female , Immunohistochemistry , NF-kappa B/metabolism , Neovascularization, Pathologic , Rats , Rats, Inbred F344 , Vascular Endothelial Growth Factor A/metabolism
5.
Proc SPIE Int Soc Opt Eng ; 71812009 Feb 25.
Article in English | MEDLINE | ID: mdl-24224074

ABSTRACT

A critical need has emerged for volumetric thermometry to visualize 3D temperature distributions in real time during deep hyperthermia treatments used as an adjuvant to radiation or chemotherapy for cancer. For the current effort, magnetic resonance thermal imaging (MRTI) is used to measure 2D temperature rise distributions in four cross sections of large extremity soft tissue sarcomas during hyperthermia treatments. Novel hardware and software techniques are described which improve the signal to noise ratio of MR images, minimize motion artifact from circulating coupling fluids, and provide accurate high resolution volumetric thermal dosimetry. For the first 10 extremity sarcoma patients, the mean difference between MRTI region of interest and adjacent interstitial point measurements during the period of steady state temperature was 0.85°C. With 1min temporal resolution of measurements in four image planes, this non-invasive MRTI approach has demonstrated its utility for accurate monitoring and realtime steering of heat into tumors at depth in the body.

6.
Int J Hyperthermia ; 24(2): 111-22, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18283588

ABSTRACT

The results from experimental studies indicate that hyperthermia is both an effective complementary treatment to, and a strong sensitiser of, radiotherapy and many cytotoxic drugs. Since the first international hyperthermia conference in 1975, Washington DC, techniques to increase tumour temperature have been developed and tested clinically. Hyperthermia can be applied by several methods: local hyperthermia by external or internal energy sources, perfusion hyperthermia of organs, limbs, or body cavities, and whole body hyperthermia. The clinical value of hyperthermia in combination with other treatment modalities has been shown by randomised trials. Significant improvement in clinical outcome has been demonstrated for tumours of the head and neck, breast, brain, bladder, cervix, rectum, lung, oesophagus, for melanoma and sarcoma. The addition of hyperthermia resulted in remarkably higher (complete) response rates, accompanied by improved local tumour control rates, better palliative effects, and/or better overall survival rates. Toxicity from hyperthermia cannot always be avoided, but is usually of limited clinical relevance. In spite of these good clinical results, hyperthermia has received little attention. Problems with acceptance concern the limited availability of equipment, the lack of awareness concerning clinical results, and the lack of financial resources. In this paper the most relevant literature describing the clinical effects of hyperthermia is reviewed and discussed, and means to overcome the lack of awareness and use of this modality is described.


Subject(s)
Hyperthermia, Induced , Neoadjuvant Therapy , Neoplasms/therapy , Combined Modality Therapy , Humans , Hyperthermia, Induced/economics , Hyperthermia, Induced/methods , Hyperthermia, Induced/trends , International Cooperation , Neoadjuvant Therapy/economics , Neoadjuvant Therapy/methods , Neoadjuvant Therapy/trends
7.
Br J Cancer ; 97(6): 735-40, 2007 Sep 17.
Article in English | MEDLINE | ID: mdl-17712313

ABSTRACT

Imatinib, an inhibitor of PDGF-Rbeta and other tyrosine kinase receptors, has been shown to decrease microvessel density and interstitial fluid pressure in solid tumours, thereby improving subsequent delivery of small molecules. The purpose of this study was to test whether pretreatment with imatinib increases the efficacy of traditional chemotherapy in mice bearing non-small cell lung carcinoma xenografts, and to investigate the effects of imatinib on liposomal drug delivery. Efficacy treatment groups included (n=9-10): saline control, imatinib alone (oral gavage, 100 mg kg(-1) x 7 days), docetaxel alone (10 mg kg(-1) i.p. 2 x /week until killing), and imatinib plus docetaxel (started on day 7 of imatinib). Tumours were monitored until they reached four times the initial treatment volume (4 x V) or 28 days. A separate experiment compared tumour doxorubicin concentrations (using high performance liquid chromatography) 24 h after treatment with liposomal doxorubicin alone (6 mg kg(-1) i.v., n=9) or imatinib plus liposomal doxorubicin (n=16). Imatinib plus docetaxel resulted in significantly improved antitumour efficacy (0/10 animals reached 4 x V by 28 days) when compared to docetaxel alone (3/9 reached 4 x V, P=0.014) or imatinib alone (9/10 reached 4 x V, P=0.025). Pretreatment with imatinib also significantly increased tumour concentrations of liposomal doxorubicin. Overall, these preclinical studies emphasise the potential of imatinib as an adjunct to small molecule or liposomal chemotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Piperazines/pharmacology , Pyrimidines/pharmacology , Animals , Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Benzamides , Chromatography, High Pressure Liquid , Docetaxel , Doxorubicin/administration & dosage , Drug Administration Schedule , Female , Imatinib Mesylate , Immunohistochemistry , Liposomes , Mice , Mice, Nude , Piperazines/pharmacokinetics , Pyrimidines/pharmacokinetics , Taxoids/administration & dosage , Xenograft Model Antitumor Assays
8.
Br J Cancer ; 95(8): 1013-9, 2006 Oct 23.
Article in English | MEDLINE | ID: mdl-17003785

ABSTRACT

Elevated intratumoral interstitial fluid pressure (IFP) and tumour hypoxia are independent predictive factors for poor survival and poor treatment response in cancer patients. However, the relationship between IFP and tumour hypoxia has not yet been clearly established. Preclinical studies have shown that lowering IFP improves treatment response to cytotoxic therapy. Interstitial fluid pressure can be reduced by inhibition of phosphorylated platelet-derived growth factor receptor-beta (p-PDGFR-beta), a tyrosine kinase receptor frequently overexpressed in cancer stroma, and/or by inhibition of VEGF, a growth factor commonly overexpressed in tumours overexpressing p-PDGFR-beta. We hypothesised that Imatinib, a specific PDGFR-beta inhibitor will, in addition to p-PDGFR-beta inhibition, downregulate VEGF, decrease IFP and improve tumour oxygenation. A549 human lung adenocarcinoma xenografts overexpressing PDGFR-beta were grown in nude mice. Tumour-bearing animals were randomised to control and treatment groups (Imatinib 50 mg kg(-1) via gavage for 4 days). Interstitial fluid pressure was measured in both groups before and after treatment. EF5, a hypoxia marker, was administered 3 h before being killed. Tumours were sectioned and stained for p-PDGFR-beta, VEGF and EF5 binding. Stained sections were viewed with a fluorescence microscope and image analysis was performed. Imatinib treatment resulted in significant reduction of p-PDGFR-beta, VEGF and IFP. Tumour oxygenation was also significantly improved. This study shows that p-PDGFR-beta-overexpressing tumours can be effectively treated with Imatinib to decrease tumour IFP. Importantly, this is the first study demonstrating that Imatinib treatment improves tumour oxygenation and downregulates tumour VEGF expression.


Subject(s)
Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Oxygen/metabolism , Piperazines/pharmacology , Pyrimidines/pharmacology , Receptor, Platelet-Derived Growth Factor beta/metabolism , Vascular Endothelial Growth Factor A/metabolism , Adenocarcinoma/drug therapy , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Benzamides , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line, Tumor , Extracellular Fluid/drug effects , Extracellular Fluid/physiology , Female , Humans , Imatinib Mesylate , Immunohistochemistry , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Mice , Mice, Nude , Microscopy, Fluorescence/methods , Models, Biological , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Neovascularization, Pathologic/prevention & control , Phosphorylation/drug effects , Piperazines/therapeutic use , Platelet Endothelial Cell Adhesion Molecule-1/analysis , Pressure , Pyrimidines/therapeutic use , Random Allocation , Receptor, Platelet-Derived Growth Factor beta/analysis , Vascular Endothelial Growth Factor A/analysis , Xenograft Model Antitumor Assays
9.
Int J Hyperthermia ; 22(4): 263-73, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16754348

ABSTRACT

PURPOSE: It has been well established that inadequate blood supply combined with high metabolic rates of oxygen consumption results in areas of low oxygen tension (<1%) within malignant tumours and that elevating tumour temperatures above 39 degrees Celsius results in significant improvement in tumour oxygenation. Macrophages play a dual role in tumour initiation and progression having both pro-tumour and anti-tumour effects. However, the response of macrophages to heat within a hypoxic environment has not yet been clearly defined. METHODS: Raw 264.7 murine macrophages were incubated under normoxia and chronic hypoxia at temperatures ranging from 37-43 degrees Celsius. Under normoxia at 41 degrees Celsius, macrophages start to release significant levels of superoxide. The combination of heat with hypoxia constitutes an additional stimulus leading to increased respiratory burst of macrophages. RESULTS: The high levels of superoxide were found to be associated with changes in macrophage production of pro-angiogenic cytokines. While hypoxia alone (37 degrees Celsius) increased levels of hypoxia inducible factor-1alpha (HIF-1alpha) in macrophages, the combination of hypoxia and mild hyperthermia (39-41 degrees Celsius) induced a strong reduction in HIF-1alpha expression. The HIF-regulated vascular endothelial growth factor (VEGF) decreased simultaneously, revealing that heat inhibits both HIF-1alpha stabilization and transcriptional activity. CONCLUSION: The data suggest that temperatures which are readily achievable in the clinic (39-41 degrees Celsius) might be optimal for maximizing hyperthermic response. At higher temperatures, these effects are reversed, thereby limiting the therapeutic benefits of more severe hyperthermic exposure.


Subject(s)
Hot Temperature , Hyperthermia, Induced , Hypoxia/metabolism , Macrophages/metabolism , Neovascularization, Physiologic/physiology , Reactive Oxygen Species/metabolism , Animals , Cell Line , Cytokines/metabolism , Hypoxia-Inducible Factor 1, alpha Subunit/analysis , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Hypoxia-Inducible Factor 1, alpha Subunit/physiology , Mice , Neoplasms/metabolism , Neoplasms/therapy , Oxygen Consumption/physiology , Respiratory Burst/physiology , Superoxides/metabolism , Temperature , Vascular Endothelial Growth Factor A/metabolism
10.
Br J Cancer ; 93(12): 1350-5, 2005 Dec 12.
Article in English | MEDLINE | ID: mdl-16288305

ABSTRACT

Tumour hypoxia has been shown to increase mutation rate, angiogenesis, and metastatic potential, and decrease response to conventional therapeutics. Improved tumour oxygenation should translate into increased treatment response. Exogenous recombinant erythropoietin (rEpo) has been recently shown to increase tumour oxygenation in a mammary carcinoma model. The mechanism of this action is not yet understood completely. The presence of Epo and its receptor (EpoR) have been demonstrated on several normal and neoplastic tissues, including blood vessels and various solid tumours. In addition, rEpo has been shown in two recent prospective, randomized clinical trials to negatively impact treatment outcome. In this study, we attempt to characterize the direct effects of rEpo on tumour growth and angiogenesis in two separate rodent carcinomas. The effect of rEpo on R3230 rat mammary adenocarcinomas, CT-26 mouse colon carcinomas, HCT-116 human colon carcinomas, and FaDu human head and neck tumours, all of which express EpoR, was examined. There were no differences in tumour growth or proliferation (measured by Ki-67) between placebo-treated and rEpo-treated tumours. In the mammary window chamber, vascular length density (VLD) measurements in serial images of both placebo-treated and Epo-treated rats revealed no difference in angiogenesis between the Epo-treated tumours and placebo-treated tumours at any time point. These experiments are important because they suggest that the recent clinical detriment seen with the use of Epo is not due to its tumour growth effects or angiogenesis. These studies also suggest that further preclinical studies need to examine rEpo's direct tumour effects in efforts to improve the therapeutic benefits of Epo in solid tumour patients.


Subject(s)
Carcinoma/pathology , Cell Proliferation/drug effects , Colonic Neoplasms/pathology , Erythropoietin/pharmacology , Head and Neck Neoplasms/pathology , Mammary Neoplasms, Animal/pathology , Neovascularization, Pathologic , Animals , Cell Hypoxia , Humans , Mice , Placebos , Random Allocation , Rats , Recombinant Proteins , Tumor Cells, Cultured
11.
Int J Hyperthermia ; 20(5): 477-89, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15277021

ABSTRACT

The objectives of this study were to compare the effects of two vasodilators, sodium nitroprusside (SNP) and calcitonin gene-related peptide (CGRP) on mean arterial pressure (MAP), heart rate (HR) and temperatures in tumour and surrounding normal tissue during local hyperthermia treatment. Eleven tumour-bearing pet dogs with spontaneous soft tissue sarcomas were given SNP intravenously during local hyperthermia. The drug infusion rate was adjusted to maintain a 20% decrease in MAP. The median (95% CI) increase in the temperature distribution descriptors T(90) and T(50) was 0.2 degrees C (0.0-0.4 degrees C, p = 0.02) and 0.4 degrees C (0.1-0.7 degrees C, p = 0.02), respectively, in tumour. Normal subcutaneous tissue temperatures were mildly increased but remained below the threshold for thermal injury. The effects of CGRP were investigated in six tumour-bearing dogs following a protocol similar to that used for SNP. The median (interquartile (IQ) range) decrease in mean arterial pressure was 19% (15-26%) after CGRP administration and a significant increase was seen in tumour but not normal subcutaneous tissue temperatures. The median (95% CI) increase in the temperature distribution descriptors T(90) and T(50) was 0.5 degrees C (0.1-1.6 degrees C, p = 0.03) and 0.8 degrees C (0.1-1.6 degrees C, p = 0.13), respectively. Administration of SNP or CGRP did not result in local or systemic toxicity in tumour-bearing dogs. However, the magnitude of increase in tumour temperatures was not sufficient to improve the likelihood of increased response rates. Therefore, there is little justification for translation of this approach to human trials using conventional local hyperthermia.


Subject(s)
Calcitonin Gene-Related Peptide/therapeutic use , Dog Diseases/therapy , Nitroprusside/therapeutic use , Sarcoma/veterinary , Soft Tissue Neoplasms/veterinary , Vasodilator Agents/therapeutic use , Animals , Blood Pressure/drug effects , Combined Modality Therapy , Dog Diseases/drug therapy , Dog Diseases/physiopathology , Dog Diseases/radiotherapy , Dogs , Hyperthermia, Induced , Sarcoma/drug therapy , Sarcoma/radiotherapy , Sarcoma/therapy , Soft Tissue Neoplasms/drug therapy , Soft Tissue Neoplasms/radiotherapy , Soft Tissue Neoplasms/therapy
12.
Int J Hyperthermia ; 20(2): 163-74, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15195511

ABSTRACT

The objective of this review is to evaluate hyperthermia related changes in tumor physiologic parameters and their relevance for tumor radiosensitization with particular emphases on tumor oxygenation. Elevation of temperature above the physiological level causes changes in blood flow, vascular permeability, metabolism, and tumor oxygenation. These changes in addition to the cellular effects such as direct cytotoxicity, inhibition of potentially lethal damage and sublethal damage repair, have an important influence on the efficacy of radiotherapy. There is now clear evidence that in a variety of rodent and canine, as well as human tumors, the changes in tumor oxygenation status caused by hyperthermia are temperature dependent and this relationship may greatly influence the response of tumors to thermoradiotherapy. The improvement of tumor oxygenation after mild hyperthermia, which often lasts for as long as 24-48 h after heating, may increase the likelihood of a positive response of tumors to radiation therapy. Furthermore, the activity of some chemotherapy drugs is also oxygen dependent, therefore, the heat-induced increase in tumor oxygenation may significantly increase the effectiveness of thermoradiotherapy in combination with certain chemotherapy drugs. Further investigations remain to be conducted to obtain clearer insights into the relationship between thermal parameters, oxygenation and response of human tumors to hyperthermia in combination with radiotherapy and/or chemotherapy.


Subject(s)
Hyperthermia, Induced , Oxygen/metabolism , Radiation Tolerance/physiology , Regional Blood Flow/physiology , Animals , Humans
13.
Int J Hyperthermia ; 19(5): 498-506, 2003.
Article in English | MEDLINE | ID: mdl-12944165

ABSTRACT

The objective of this study was to determine whether neoadjuvant chemotherapy in combination with hyperthermia (HT) would improve oxygenation in locally advanced breast tumours. The study describes a new optimized ultrasound guided technique of pO2 measurement using Eppendorf polarographic oxygen probes in 18 stage IIB-III breast cancer patients. Prior to treatment, tumour hypoxia (median pO2<10 mmHg) was present in 11/18 patients (average median pO2=3.2 mmHg). Seven patients had well oxygenated tumours (median pO2 of 48.3 mmHg). Eight patients with hypoxic tumours prior to treatment had a significant improvement (p=0.0008) in tumour pO2 after treatment (pO2 increased to 19.2 mmHg). In three patients, tumours remained hypoxic (average median pO2=4.5 mmHg). The advantages of the ultrasound guided pO2 probe are in the accuracy of the Eppendorf electrode placement in tumour tissue, the ability to monitor electrode movement through the tumour tissue during the measurement and the ability to avoid electrode placement near or in large blood vessels by using colour Doppler imaging. The results of this preliminary study suggest that the combination of neoadjuvant chemotherapy and hyperthermia improves oxygenation in locally advanced breast tumours that are initially hypoxic.


Subject(s)
Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Hyperthermia, Induced , Neoadjuvant Therapy/methods , Oxygen/metabolism , Antibiotics, Antineoplastic/administration & dosage , Antineoplastic Agents, Phytogenic/administration & dosage , Breast Neoplasms/diagnostic imaging , Combined Modality Therapy , Doxorubicin/administration & dosage , Electrodes , Female , Humans , Hypoxia , Paclitaxel/administration & dosage , Partial Pressure , Ultrasonography, Doppler, Color
14.
Int J Radiat Oncol Biol Phys ; 50(4): 851-5, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11429211

ABSTRACT

PURPOSE: The purpose of this study was to determine whether or not hypoxia develops in rat lung tissue after radiation. METHODS AND MATERIALS: Fisher-344 rats were irradiated to the right hemithorax using a single dose of 28 Gy. Pulmonary function was assessed by measuring the changes in respiratory rate every 2 weeks, for 6 months after irradiation. The hypoxia marker was administered 3 h before euthanasia. The tissues were harvested at 6 weeks and 6 months after irradiation and processed for immunohistochemistry. RESULTS: A moderate hypoxia was detected in the rat lungs at 6 weeks after irradiation, before the onset of functional or histopathologic changes. The more severe hypoxia, that developed at the later time points (6 months) after irradiation, was associated with a significant increase in macrophage activity, collagen deposition, lung fibrosis, and elevation in the respiratory rate. Immunohistochemistry studies revealed an increase in TGF-beta, VEGF, and CD-31 endothelial cell marker, suggesting a hypoxia-mediated activation of the profibrinogenic and proangiogenic pathways. CONCLUSION: A new paradigm of radiation-induced lung injury should consider postradiation hypoxia to be an important contributing factor mediating a continuous production of a number of inflammatory and fibrogenic cytokines.


Subject(s)
Cell Hypoxia/physiology , Lung/radiation effects , Radiation Injuries, Experimental/physiopathology , Animals , Endothelial Growth Factors/metabolism , Female , Fibrosis , Lung/pathology , Lung/physiopathology , Lymphokines/metabolism , Macrophages/metabolism , Radiation Injuries, Experimental/etiology , Radiation Injuries, Experimental/metabolism , Radiation Tolerance , Rats , Rats, Inbred F344 , Transforming Growth Factor beta/metabolism , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
15.
Radiother Oncol ; 58(3): 313-6, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11230893

ABSTRACT

The purpose of this study is to define differences in radiation sensitivity among rat strains using breathing frequency and lung perfusion as end points of radiation-induced lung injury. The results have confirmed previous findings in mice showing that under stringently controlled iso-dose/volume irradiation conditions, substantial differences can be found in susceptibility to functional lung damage after radiation.


Subject(s)
Disease Models, Animal , Lung Diseases/etiology , Lung/radiation effects , Radiation Injuries , Rats, Inbred Strains , Animals , Disease Susceptibility , Lung/diagnostic imaging , Lung Diseases/diagnostic imaging , Lung Diseases/physiopathology , Pulmonary Circulation/radiation effects , Radiation Dosage , Radiation Injuries/diagnostic imaging , Radiation Injuries/physiopathology , Radiation Tolerance , Radionuclide Imaging , Rats , Rats, Inbred F344 , Rats, Sprague-Dawley , Rats, Wistar , Respiration/radiation effects
16.
Semin Radiat Oncol ; 10(4): 296-307, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11040330

ABSTRACT

Radiation therapy (RT) is frequently used to treat patients with tumors in and around the thorax. Clinical radiation pneumonitis is a common side effect, occurring in 5% to 20% of patients. Efforts to identify patients at risk for pneumonitis have focused on physical factors, such as dose and volume. Recently, the underlying molecular biological mechanisms behind RT-induced lung injury have come under study. Improved knowledge of the molecular events associated with RT-induced lung injury may translate into a better ability to individualized therapy. This review discusses our current understanding of the physical and molecular factors contributing to RT-induced pulmonary injury.


Subject(s)
Carcinoma, Non-Small-Cell Lung/radiotherapy , Lung Neoplasms/radiotherapy , Radiation Pneumonitis/etiology , Radiation Pneumonitis/metabolism , Transforming Growth Factor beta/metabolism , Carcinoma, Non-Small-Cell Lung/metabolism , Humans , Lung Neoplasms/metabolism , Models, Biological , Radiotherapy Dosage , Risk Factors
17.
Clin Cancer Res ; 6(6): 2501-5, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10873105

ABSTRACT

Recently, it has been suggested that the cellular uptake of chemotherapeutic drugs may be dependent on the pH gradient between the intracellular (pHi) and extracellular (pHe) compartments. It has been demonstrated in murine tumor models that the extracellular environment is acidic, relative to the intracellular environment, thus favoring preferential accumulation of drugs that are weak acids into cells. However, concomitant measurements of pHi and pHe in spontaneous tumors have not been reported, so it is not certain how well the murine results translate to the clinical scenario. In this study, both types of measurements were performed in dogs with spontaneous malignant soft tissue tumors. On average, pHe was more acidic than pHi, with maintenance of a more physiologically balanced intracellular tumor environment. However, the magnitude of the gradient varied widely, and individual tumors had both positive and negative pH gradients (pHi - pHe). These data suggest that the magnitude and direction of the pH gradient may need to be measured for individual patient tumors and/or that manipulation of pHe may be required if exploitation of the pH gradient is to be achieved for tumor-selective augmentation of intracellular drug delivery.


Subject(s)
Hydrogen-Ion Concentration , Soft Tissue Neoplasms/etiology , Soft Tissue Neoplasms/veterinary , Animals , Antineoplastic Agents, Alkylating/pharmacology , Cell Membrane/metabolism , Chlorambucil/pharmacology , Dogs , Soft Tissue Neoplasms/chemistry , Soft Tissue Neoplasms/metabolism
18.
Int J Radiat Biol ; 76(4): 463-8, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10815625

ABSTRACT

PURPOSE: To study the dose-related incidence of severe symptomatic pneumonitis following fractionated irradiation applied to three different volumes of lung in normal beagle dogs. MATERIALS AND METHODS: A three-dimensional treatment planning system was used to design mediastinal fields of increasing width to irradiate 33%, 67% or 100% of both lungs combined in 128 normal beagle dogs. Total doses, ranging from 27 to 72 Gy, were delivered in 1.5 Gy fractions over 6 weeks. RESULTS: No dogs irradiated to 33% of their total lung volume developed severe symptomatic pneumonitis. In the 67% volume group, logistic fit of the data showed a dose-response curve with a 50% probability of developing severe symptomatic pneumonitis (ED50) after a total dose of 56.0 Gy (52.2-66.0 Gy, 95% confidence interval, CI). The more clinically relevant ED5 for the first 6 months after irradiation of 67% of the lung was 48.1 Gy (18.5-52.0 Gy, 95% CI). The ED50 and ED5 values after irradiation of the whole lung (100%) were 44.1 Gy (41.2-53.5Gy, 95% CI) and 39.1 Gy (8.8-41.8 Gy, 95% CI) respectively. CONCLUSION: Severe symptomatic pneumonitis proved to be a very informative volume-effect endpoint, clearly demonstrating that irradiated lung volume is a critical parameter to be considered in assigning thoracic radiotherapy treatment parameters. Volume effects in lung are dependent on the compensatory capacity of the nonirradiated lung. Underlying pathophysiology of irradiated tissue, as well as decreased compensatory capacity of nonirradiated tissue may have a strong effect on the dose-volume response.


Subject(s)
Radiation Pneumonitis/etiology , Animals , Dogs , Dose Fractionation, Radiation , Dose-Response Relationship, Radiation , Female , Lethal Dose 50 , Male , Radiation Tolerance
19.
Int J Radiat Biol ; 76(4): 511-6, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10815631

ABSTRACT

PURPOSE: To determine whether changes in TGF-beta plasma levels during radiation therapy may be useful in predicting radiation-induced pulmonary injury and tumour response in non-small-cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: Plasma TGF-beta was investigated in 27 patients with stage III NSCLC, who were treated with 60 Gy (2Gy/day) radiotherapy with or without carboplatin. TGF-beta was measured prior to beginning radiotherapy and weekly during treatment; evaluated as a ratio between TGF-beta levels obtained during treatment and the pretreatment TGF-beta level. The endpoints of the study were development of symptomatic radiation pneumonitis and tumour response. RESULTS: Nine of the 27 patients developed pneumonitis. The patients who developed pneumonitis had high persistent TGF-beta levels throughout the course of treatment (TGF-beta ratio>1), whereas the TGF-beta levels in patients who did not develop pneumonitis were unchanged or declined towards normal (TGF-beta ratio < 1). Patients who responded to treatment had low or normal TGF-beta levels during treatment compared with patients who failed to respond. Other parameters such as pretreatment TGF-beta values, carboplatin treatment or field size did not appear to have a significant effect, which is probably due to the small number of patients entered in the study. CONCLUSION: This pilot study, with a limited number of patients, suggests the hypothesis that elevated TGF-beta levels during radiotherapy may not only indicate patients with a higher risk of developing pulmonary toxicity but also patients with a higher risk of treatment failure. This remains to be tested in a larger clinical study.


Subject(s)
Lung Neoplasms/radiotherapy , Lung/radiation effects , Radiation Injuries/etiology , Radiotherapy/adverse effects , Transforming Growth Factor beta/physiology , Adult , Aged , Humans , Middle Aged , Pilot Projects , Transforming Growth Factor beta/blood , Treatment Failure
20.
Thorax ; 55(3): 245-6, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10679546

ABSTRACT

Superior vena cava syndrome is most often caused by lung carcinoma. Two cases are described in whom venous obstruction in the superior mediastinum was caused by local vascular fibrosis due to radiotherapy five and seven years earlier. The development of radiation injury to greater vessels is discussed, together with the possibilities for treatment of superior vena cava syndrome.


Subject(s)
Pulmonary Fibrosis/etiology , Radiation Injuries/complications , Superior Vena Cava Syndrome/etiology , Adult , Humans , Lung Neoplasms/radiotherapy , Male , Middle Aged , Orbital Neoplasms/radiotherapy , Superior Vena Cava Syndrome/surgery , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...